BioMarin Pharmaceutical (BM8) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BM8 Analyst Ratings

Moderate Buy

11 Buy

5 Hold

0 Sell

Based on 16 analysts giving stock ratings to

BioMarin

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BM8 Stock 12 Month Forecast

Average Price Target

€74.01

▲(37.83% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is €74.01 with a high forecast of €101.47 and a low forecast of €50.73. The average price target represents a 37.83% change from the last price of €53.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"€43","102":"€102","57.75":"€57.8","72.5":"€72.5","87.25":"€87.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101.4684168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€101.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.0127543542,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€74.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.7342084,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€50.73</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,57.75,72.5,87.25,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.65,50.86680129230769,55.083602584615385,59.30040387692307,63.51720516923076,67.73400646153846,71.95080775384615,76.16760904615384,80.38441033846154,84.60121163076923,88.81801292307692,93.03481421538461,97.25161550769229,{"y":101.4684168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.65,48.75482725801538,50.859654516030766,52.96448177404615,55.06930903206154,57.174136290076916,59.27896354809231,61.38379080610769,63.488618064123074,65.59344532213845,67.69827258015384,69.80309983816923,71.90792709618461,{"y":74.0127543542,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.65,46.96416987692307,47.278339753846154,47.59250963076923,47.90667950769231,48.220849384615384,48.53501926153846,48.84918913846154,49.163359015384614,49.47752889230769,49.79169876923077,50.105868646153844,50.420038523076926,{"y":50.7342084,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€101.47

Average Price Target€74.01

Lowest Price Target€50.73

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mohit Bansal

Wells Fargo

€59.38→€63.62

Buy

18.47%

Upside

Reiterated

02/18/26

BioMarin price target raised to $75 from $70 at Wells FargoBioMarin price target raised to $75 from $70 at Wells Fargo

William Pickering

Bernstein

€74.65→€76.34

Buy

42.16%

Upside

Reiterated

02/18/26

BioMarin Pharmaceutical (BMRN) Receives a Buy from Bernstein

Mitchell Kapoor

H.C. Wainwright

€50.9

Hold

-5.22%

Downside

Reiterated

02/17/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (NYSE: AMN), Vanda (NASDAQ: VNDA) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Whitney Ijem

Canaccord Genuity

€83.13

Buy

54.80%

Upside

Reiterated

02/13/26

BioMarin Pharmaceutical (BMRN) Receives a Buy from Canaccord Genuity

Akash Tewari

Jefferies

€95.85

Buy

78.50%

Upside

Reiterated

02/12/26

BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies

Allison Bratzel

Piper Sandler

€103.49→€71.25

Buy

32.69%

Upside

Reiterated

02/06/26

BioMarin price target lowered to $84 from $122 at Piper SandlerBioMarin price target lowered to $84 from $122 at Piper Sandler

Eliana Merle

Barclays

€67.86

Buy

26.37%

Upside

Reiterated

01/27/26

BioMarin assumed with an Overweight at BarclaysBioMarin assumed with an Overweight at Barclays

Cory Kasimov

Evercore ISI

€93.31

Buy

73.76%

Upside

Reiterated

01/13/26

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

―

Hold

―

Reiterated

01/13/26

Balanced View on BioMarin: Solid Near-Term Guidance Offset by Voxzogo Competitive Risks and Roctavian Challenges, Supporting a Hold Rating

Yun Zhong

Wedbush

€79.74

Buy

48.48%

Upside

Reiterated

01/13/26

BioMarin: Sustained Double-Digit Growth Story Underpinned by Voxzogo Leadership, Advancing Rare-Disease Pipeline, and Accretive Amicus Acquisition

Phil Nadeau

TD Cowen

€101.79

Buy

89.55%

Upside

Reiterated

01/12/26

BioMarin: Buy Rating Reaffirmed on Strong 2025 Outlook, Promising Pipeline, and Accretive M&A

Luca Issi

RBC Capital

€55.98

Hold

4.25%

Upside

Reiterated

01/08/26

Analysts Conflicted on These Healthcare Names: Cormedix (NASDAQ: CRMD), BioMarin Pharmaceutical (NASDAQ: BMRN) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joon Lee

Truist Financial

€67.86→€84.83

Buy

57.96%

Upside

Reiterated

12/23/25

Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Jason Gerberry

Bank of America Securities

€86.52

Buy

61.12%

Upside

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Paul Matteis

Stifel Nicolaus

€51.74

Hold

-3.64%

Downside

Assigned

12/19/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Pfizer (NYSE: PFE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mohit Bansal

Wells Fargo

€59.38→€63.62

Buy

18.47%

Upside

Reiterated

02/18/26

BioMarin price target raised to $75 from $70 at Wells FargoBioMarin price target raised to $75 from $70 at Wells Fargo

William Pickering

Bernstein

€74.65→€76.34

Buy

42.16%

Upside

Reiterated

02/18/26

BioMarin Pharmaceutical (BMRN) Receives a Buy from Bernstein

Mitchell Kapoor

H.C. Wainwright

€50.9

Hold

-5.22%

Downside

Reiterated

02/17/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (NYSE: AMN), Vanda (NASDAQ: VNDA) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Whitney Ijem

Canaccord Genuity

€83.13

Buy

54.80%

Upside

Reiterated

02/13/26

BioMarin Pharmaceutical (BMRN) Receives a Buy from Canaccord Genuity

Akash Tewari

Jefferies

€95.85

Buy

78.50%

Upside

Reiterated

02/12/26

BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies

Allison Bratzel

Piper Sandler

€103.49→€71.25

Buy

32.69%

Upside

Reiterated

02/06/26

BioMarin price target lowered to $84 from $122 at Piper SandlerBioMarin price target lowered to $84 from $122 at Piper Sandler

Eliana Merle

Barclays

€67.86

Buy

26.37%

Upside

Reiterated

01/27/26

BioMarin assumed with an Overweight at BarclaysBioMarin assumed with an Overweight at Barclays

Cory Kasimov

Evercore ISI

€93.31

Buy

73.76%

Upside

Reiterated

01/13/26

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

―

Hold

―

Reiterated

01/13/26

Balanced View on BioMarin: Solid Near-Term Guidance Offset by Voxzogo Competitive Risks and Roctavian Challenges, Supporting a Hold Rating

Yun Zhong

Wedbush

€79.74

Buy

48.48%

Upside

Reiterated

01/13/26

BioMarin: Sustained Double-Digit Growth Story Underpinned by Voxzogo Leadership, Advancing Rare-Disease Pipeline, and Accretive Amicus Acquisition

Phil Nadeau

TD Cowen

€101.79

Buy

89.55%

Upside

Reiterated

01/12/26

BioMarin: Buy Rating Reaffirmed on Strong 2025 Outlook, Promising Pipeline, and Accretive M&A

Luca Issi

RBC Capital

€55.98

Hold

4.25%

Upside

Reiterated

01/08/26

Analysts Conflicted on These Healthcare Names: Cormedix (NASDAQ: CRMD), BioMarin Pharmaceutical (NASDAQ: BMRN) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joon Lee

Truist Financial

€67.86→€84.83

Buy

57.96%

Upside

Reiterated

12/23/25

Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Jason Gerberry

Bank of America Securities

€86.52

Buy

61.12%

Upside

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Paul Matteis

Stifel Nicolaus

€51.74

Hold

-3.64%

Downside

Assigned

12/19/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Pfizer (NYSE: PFE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months

xxx

Success Rate

15/36 ratings generated profit

Average Return

-0.46%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.46% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

22/43 ratings generated profit

Average Return

-2.79%

reiterated a buy rating last month

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 51.16% of your transactions generating a profit, with an average return of -2.79% per trade.

2 Years

xxx

Success Rate

10/25 ratings generated profit

Average Return

-7.01%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -7.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BM8 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BM8 has received 33 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BM8 average Analyst price target in the past 3 months is 74.01.

Each month's total comprises the sum of three months' worth of ratings.

BM8 Financial Forecast

BM8 Earnings Forecast

Currently, no earnings data available.

BM8 Sales Forecast

Currently, no sales data available.

BM8 Stock Forecast FAQ

What is DE:BM8’s average 12-month price target, according to analysts?

Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 74.01.

What is DE:BM8’s upside potential, based on the analysts’ average price target?

BioMarin Pharmaceutical has 37.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BioMarin Pharmaceutical a Buy, Sell or Hold?

BioMarin Pharmaceutical has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.

What is BioMarin Pharmaceutical’s share price target?

The average share price target for BioMarin Pharmaceutical is 74.01. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €101.47 ,and the lowest forecast is €50.73. The average share price target represents 37.83% Increase from the current price of €53.7.

What do analysts say about BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of BioMarin Pharmaceutical?

To buy shares of DE:BM8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

BioMarin Pharmaceutical (BM8) Stock Forecast & Price Target

BM8 Analyst Ratings

BM8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioMarin Pharmaceutical

BM8 Analyst Recommendation Trends

BM8 Financial Forecast

BM8 Earnings Forecast

BM8 Sales Forecast

BM8 Stock Forecast FAQ

Detailed List of Analyst Forecasts